Your browser doesn't support javascript.
loading
The impact of COPD on the private healthcare system in Brazil: an economic analysis / Impacto da DPOC no sistema de saúde privado no Brasil: uma análise econômica
Nascimento, Oliver Augusto; Saturnino, Luciana Tarbes Mattana; Santos, Felipe Moares dos; Silva, Danielle Oliveira da; Gazzotti, Mariana Rodrigues; Martins, Franco Chies; Gomes, Ana Luisa Bessa Bacellar; Viana, Karynna Pimentel; Afonso-Cristancho, Rafael; Rodrigues, Claudia Soares.
Affiliation
  • Nascimento, Oliver Augusto; GlaxoSmithKline. Rio de Janeiro. BR
  • Saturnino, Luciana Tarbes Mattana; GlaxoSmithKline. Rio de Janeiro. BR
  • Santos, Felipe Moares dos; GlaxoSmithKline. Rio de Janeiro. BR
  • Silva, Danielle Oliveira da; GlaxoSmithKline. Rio de Janeiro. BR
  • Gazzotti, Mariana Rodrigues; GlaxoSmithKline. Rio de Janeiro. BR
  • Martins, Franco Chies; GlaxoSmithKline. Rio de Janeiro. BR
  • Gomes, Ana Luisa Bessa Bacellar; Orizon. São Paulo. BR
  • Viana, Karynna Pimentel; GlaxoSmithKline. Rio de Janeiro. BR
  • Afonso-Cristancho, Rafael; GlaxoSmithKline. Collegeville. US
  • Rodrigues, Claudia Soares; GlaxoSmithKline. Rio de Janeiro. BR
J. bras. econ. saúde (Impr.) ; 15(1): 59-66, Abril/2023.
Article in English, Portuguese | LILACS, ECOS | ID: biblio-1437952
Responsible library: BR600
Localization: BR600
ABSTRACT

Objective:

To assess healthcare resource utilization and hospitalization costs of patients with chronic obstructive pulmonary disease (COPD) exacerbations in the Brazilian private healthcare system.

Methods:

A retrospective cohort study, considering data from an administrative database of a private company (Orizon). Patients aged ≥40 years old and with at least one COPD-related claim identified by the ICD-10 code (J40 to J44) at any time during the eligibility period (January/2010 to December/2013) were included in the analysis. Follow-up was performed until December/2014, death or inactivation of a health plan. Sociodemographic characteristics, number of emergency visits, hospital admissions (number and length of stay), length of hospital stay in an intensive care unit (ICU), number of severe COPD exacerbations, therapeutic approach, and hospitalization costs were assessed.

Results:

The analysis included 8,254 COPD patients. Emergency visits, hospital admission, and exacerbation rates were 0.4, 0.2, and 0.1 per person-year, respectively. The mean length of hospital stays and the length of stay of patients requiring or not ICU stay were 16.6 (SD = 77.0), 8.7 (SD = 36.9), and 27.6 (SD = 109.7), respectively. Mean costs associated to emergency department visits and hospitalizations were 258.2 BRL (SD = 383.1) and 38,165.4 BRL (SD = 124,683.5), respectively. Hospitalizations costs without ICU stay were 11,810.1 BRL (SD = 31,144.1) and 74,585.3 BRL (SD = 182,808.1) for those with ICU utilization.

Conclusion:

Costs for COPD management during disease exacerbation are very high and may reach almost 75 thousand BRL per hospitalization. The prevention of COPD exacerbations and better disease control may reduce the economic burden on the private healthcare system in Brazil.
RESUMO

Objetivo:

Avaliar a utilização de recursos e custos de pacientes com exacerbação da doença pulmonar obstrutiva crônica (DPOC) no sistema de saúde suplementar (SSS) do Brasil.

Métodos:

Estudo de coorte retrospectiva, considerando banco de dados administrativo de uma empresa privada (Orizon). Pacientes com ≥40 anos e pelo menos um registro de admissão relacionado à DPOC identificado com CID-10 J40-J44, entre janeiro/2010 e dezembro/2013, foram incluídos e acompanhados até dezembro/2014, morte ou inativação no plano. Características sociodemográficas, número de visitas de emergência, admissões hospitalares (número e tempo de hospitalização), tempo de hospitalização em unidade de terapia intensiva (UTI), número de exacerbações graves, estratégias terapêuticas e custos hospitalares foram as variáveis analisadas.

Resultados:

A análise incluiu 8.254 pacientes com DPOC. As taxas de visita à emergência, internação hospitalar e exacerbação da doença foram de 0,4, 0,2 e 0,1 por pessoa-ano, respectivamente. Os tempos médios de hospitalização, hospitalização sem utilização de UTI e hospitalização com necessidade de UTI foram de 16,6 (DP = 77,0), 8,7 (DP = 36,9) e 27,6 (DP = 109,7) dias, respectivamente. Os custos médios relacionados à visita de emergência e por hospitalização foram de 258,2 BRL (DP = 383,1) e 38.165,4 BRL (DP = 124.683,5), respectivamente. Os custos para pacientes que não utilizaram UTI foram de 11.810,1 BRL (DP = 31.144,1) e de 74.585,3 BRL (DP = 182.808,1) para aqueles com necessidade desse serviço.

Conclusão:

Os custos para o manejo dos pacientes com exacerbação da DPOC são muito elevados, podendo chegar a 75.000 BRL por hospitalização. A prevenção de exacerbações e o melhor controle da doença podem reduzir esse impacto econômico no SSS.
Subject(s)


Full text: Available Collection: International databases Health context: Sustainable Health Agenda for the Americas / SDG3 - Target 3.4 Reduce premature mortality due to noncommunicable diseases Health problem: Goal 4: Health financing / Chronic Obstructive Pulmonary Disease (COPD) / Other Respiratory Diseases Database: ECOS / LILACS Main subject: Costs and Cost Analysis / Pulmonary Disease, Chronic Obstructive / Supplemental Health Type of study: Health economic evaluation / Observational study / Prognostic study / Risk factors Country/Region as subject: South America / Brazil Language: English / Portuguese Journal: J. bras. econ. saúde (Impr.) Journal subject: Medicine Year: 2023 Document type: Article Affiliation country: Brazil / United States Institution/Affiliation country: GlaxoSmithKline/BR / GlaxoSmithKline/US / Orizon/BR

Full text: Available Collection: International databases Health context: Sustainable Health Agenda for the Americas / SDG3 - Target 3.4 Reduce premature mortality due to noncommunicable diseases Health problem: Goal 4: Health financing / Chronic Obstructive Pulmonary Disease (COPD) / Other Respiratory Diseases Database: ECOS / LILACS Main subject: Costs and Cost Analysis / Pulmonary Disease, Chronic Obstructive / Supplemental Health Type of study: Health economic evaluation / Observational study / Prognostic study / Risk factors Country/Region as subject: South America / Brazil Language: English / Portuguese Journal: J. bras. econ. saúde (Impr.) Journal subject: Medicine Year: 2023 Document type: Article Affiliation country: Brazil / United States Institution/Affiliation country: GlaxoSmithKline/BR / GlaxoSmithKline/US / Orizon/BR
...